Canadian Cancer Trials Group Bulletins

Group Administrators Office

Stand Up to Cancer (SU2C) Canada Dream Team

The Canadian Cancer Trials Group is very proud to be part of the newly-funded Stand Up to Cancer Canada (SU2C)/ Canadian Breast Cancer Foundation (CBCF) Dream Team led by Drs. Tak Mak from the Princess Margaret Cancer Centre and Sam Aparacio from the British Columbia Cancer Agency in Vancouver.

SU2C is a groundbreaking initiative created to accelerate innovative cancer research that will get new therapies to patients quickly and save lives now. The SU2C Canada Breast Cancer Dream Team's fully integrated translational research model is propelling the group rapidly toward more effective, less toxic therapies for patients with three major breast cancer subtypes.

"The Canadian Cancer Trials Group is very pleased to be running the clinical trials of the promising innovative new agents arising from the Dream Team. These will hopefully turn into new options for patients with breast cancer," says Janet Dancey, Director of Canadian Cancer Trials Group.

"These four clinical trials test three new drugs all of which look promising in the laboratory," says Lesley Seymour, Director of the Investigational New Drug Program, Canadian Cancer Trials Group. "Cutting-edge translational work -- looking to better understand how these new drugs work -- will be conducted in the laboratories of the Dream Team."

The SU2C Canada-CBCF Breast Cancer Dream Team is the first to be announced since SU2C Canada was launched in 2014. The team is funded over a period of four years for $6 million provided by SU2C and by CBCF, with support from the Canadian Imperial Bank of Commerce (CIBC), and $3 million from the Ontario Institute of Cancer Research.

Please click here to read more about the Dream Team.